Skip to content
OpenCapital
Get started

Insulet PODD Accounts Receivable, Credit Loss Expense (Reversal)

Accounts Receivable, Credit Loss Expense (Reversal) at other companies

Medtronic logo
MedtronicMDT
——

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's accounts receivable, credit loss expense (reversal).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's accounts receivable, credit loss expense (reversal)?
Insulet (PODD) reported accounts receivable, credit loss expense (reversal) of $300K in Q1 2026.
How has Insulet's accounts receivable, credit loss expense (reversal) changed year-over-year?
Insulet's accounts receivable, credit loss expense (reversal) decreased by 93.6% year-over-year, from $4.7M to $300K.
What is the long-term trend for Insulet's accounts receivable, credit loss expense (reversal)?
Over 3 years (2021 to 2024), Insulet's accounts receivable, credit loss expense (reversal) has grown at a -54.1% compound annual growth rate (CAGR), from $3.1M to -$300K.